What this is
- How it works
- How it works isn't classified yet
- Tested for
- Polycythemia Vera, Beta-Thalassemia
- Main trialPhase 1
- “The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of 9MW3011 in Chinese patients with Polycythemia Vera(PV).”In the company’s words, NCT06752746 on ClinicalTrials.gov
Other drugs for Polycythemia Vera
- GivinostatItalfarmaco · Phase 3
- RusfertideProtagonist Therapeutics, Inc. · Phase 3
- AG-236Agios Pharmaceuticals, Inc. · Phase 2/3
- BomedemstatMerck & Co. · Phase 3
- Ropeginterferon alfa-2bPharmaEssentia · Phase 3
- Flonoltinib MaleateChengdu Zenitar Biomedical Technology Co., Ltd · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 31 Aug 2025 | A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera | |
| Phase 1Recruiting | Oct 2026 | A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia | |
| Phase 1Completed | 31 May 2024 | Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026